Stoyanova Lab at UCLA
@stoyanovalab
Followers
278
Following
277
Statuses
108
Lab of Dr. Tanya Stoyanova, Associate Professor of Molecular and Medical Pharmacology and of Urology at UCLA. Twitter is postdoc run.
Los Angeles, CA
Joined October 2018
My lab and I am very thankful to the National Cancer Institute for their continued support of our research on discovering new therapeutic targets and testing new treatment strategies for advanced prostate cancer.
0
2
5
I am very thankful to the Department of Defense for supporting work in our lab to test new minimally invasive approaches for detecting neuroendocrine prostate cancer and to test new therapeutic strategies for the disease.
2
2
10
Stoyanova lab is excited to share our new work on identifying Trop2 protein as a novel prognostic tissue biomarker and non-invasive urinary biomarker for prostate cancer.
1
4
15
Stoyanova lab is excited to share our study on identifying ACAA2 as a potential new molecular indicator for cancers with neuroendocrine phenotype.
1
0
9
Big congratulations to Laura for receiving the 2023 EULA and Donald S. Coffey Innovative Research Award!Fantastic work and well deserved!!! @ShiqinLiu1892 #2023SBUR
0
0
20
RT @ShiqinLiu1892: Feel honored to receive the Coffey Award. Had a great time with all the great people #2023SBUR.
0
1
0
Dr. Shiqin Liu receives the 2023 UCLA Jonsson Comprehensive Cancer Center (JCCC) Postdoctoral Fellowship Award. Her project is titled “Testing UCHL1 as a Molecular Indicator and Therapeutic Target for Neuroendocrine Prostate Cancer,” mentored by Dr. Tanya Stoyanova.
0
1
14
Christopher Massey (PhD Candidate MMP) receives 2023 Jonsson Comprehensive Cancer Center (JCCC) fellowship award! His project aims for the “Development of anti-Trop2 Antibody-based Radiopharmaceuticals for Epithelial Cancers”, mentored by Dr. Tanya Stoyanova and Dr. Peter Clark.
0
0
8
I am very thankful to the Department of Defense for supporting a new study in my lab to identify minimally invasive approaches for diagnosis of small cell lung cancer and to test new therapeutic strategies for the disease.
5
3
34